Chr. Hansen

(IN BRIEF) Novozymes and Chr. Hansen have unveiled their new collective name, ‘Novonesis,’ symbolizing a fresh beginning in the world of biosolutions. This announcement marks a significant step towards the merger of the two companies. Novonesis, which means ‘A new … Read the full press release →

(IN BRIEF) Health Canada has granted authorization for the probiotic strain Lactobacillus acidophilus DDS-1® to make health claims related to the gut-brain axis. The strain is now approved to help alleviate perceived stress, improve irritable bowel syndrome (IBS)-related quality of … Read the full press release →

(IN BRIEF) Novozymes, a global biosolutions company, has reported its first-half 2023 financial results. The company achieved 3% organic sales growth, an EBIT margin of 25% before special items, and a return on invested capital (ROIC) including goodwill of 17% … Read the full press release →

(IN BRIEF) Chr. Hansen has received approval from the EU for their 6’-SL HMO, the final addition to their MyOli™ 5 HMO Mix. This authorization allows the highest use level of 6’-SL in infant formula and follow-on formula in the … Read the full press release →